OPRA Implant System
Integrum AB · Decision date Apr 15, 2026
What did the FDA approve?
FDA records P190009/S011 as a supplement to PMA P190009, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 15, 2026.
FDA approval order statement
approval for the following changes: i) changes to the transport packaging box dimensions and configuration, ii) minor changes to the package design of the fixture components; and iii) removal of the repacking step after sterilization
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Orthopedic
- Decision date
- Apr 15, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P190009/S011
- Regulatory pathway
- PMA supplement
- Applicant
- Integrum AB
- Product code
- PJY
- Decision code
- APPR
- Decision date
- Apr 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Osseoanchored prostheses for the rehabilitation of transfemoral amputees.
- Applicant
- Integrum AB
- Product code
- PJY
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P190009/S009 · Related supplement
OPRA Implant System
P190009/S006 · Related supplement
OPRA Implant System, Abutment component
P190009/S011 received
Application receipt date recorded by FDA.
P190009/S012 · Related supplement
OPRA Implant System
P190009/S010 · Related supplement
OPRA Implant System
P190009/S011 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P190009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
OPRA Implant SystemP190009/S009 | Integrum AB | PMA supplement | Aug 14, 2025 | FDA |
OPRA Implant System, Abutment componentP190009/S006 | Integrum AB | PMA supplement | Nov 20, 2025 | FDA |
OPRA Implant SystemP190009/S012 | Integrum AB | PMA supplement | Feb 12, 2026 | FDA |
OPRA Implant SystemP190009/S010 | Integrum AB | PMA supplement | Mar 12, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Integrum AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Krokslatts Fabriker 50, Mölndal, SE-431 37
Sources and methodology
- Original FDA record: P190009/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

